allergy banner

Videos


Allergy Ranks Highest Impact Factor in Allergy



We are thrilled to announce that the 2024 journal Impact Factors stablished by Clarivate has been released, and we are immensely proud to share that Allergy has been recognised with a Impact Factor of 12.6 as the number one journal in our speciality of Allergy and Clinical Immunology. This outstanding achievement is a testament to the entire team's unwavering commitment and hard work.

The success of Allergy is rooted in several key factors:
Full Commitment and Hard Work: The dedication of our editorial and support teams has been instrumental in driving the journal to new heights.
Rapid Decisions for Submissions: Our efficient submission process ensures that authors receive timely and comprehensive feedback.
Extensive and High-Quality Reviews: We maintain rigorous peer review standards to ensure the publication of only the highest quality research.
Timely Publications: Speedy yet thorough processing of manuscripts guarantees that important research reaches the community promptly.
High Numbers of Impressions and Downloads: The significant engagement with our published papers highlights the journal’s influence and reach within the scientific community.

On behalf of the EAACI Executive Committee, it is our pleasure to extend our heartfelt gratitude to the entire Allergy team.

Special thanks to our Editor-in-Chief, Cezmi Akdis, for his visionary leadership, and our Deputy Editors, Ioana Agache and Marek Jutel, for their invaluable contributions. We also recognize the vital roles of our Associate Editors, including Heimo Breiteneder, Thomas Eiwegger, Wytske Fokkens, Emma Guttman-Yassky, David Jackson, Kari Nadeau, Robyn O’Hehir, Liam O’Mahony, Oliver Pfaar, Alexandra Santos, Claudia Traidl-Hoffmann, De Yun Wang, and Luo Zhang, along with the entire editorial board for their expertise and dedication.

In addition, our heartfelt thanks go to our Managing Editor, Laura Alberch; Graphics Editor, Anna Globinska; Social Media Editor, Ruya Kilic Ogulur; Associate Managing Editor, Marisa McGarry; Production Editor, Sathish Asokan Kannan, and Journal’s Publishing Manager, Lisbeth Cranfield.

Together, we have set a new standard of excellence in Allergy and Clinical Immunology, and we look forward to continuing this upward trajectory. Thank you to everyone who has contributed to making #Allergy a leader in our field!

Maria Torres
EAACI President

Free access

Articles


Allergen immunotherapy adverse events in adults with respiratory allergies-data from ADER: An EAACI task force report

Julijana A, Dimitrios M, George K, et al. Allergy. First published: 22 August 2024

Algorithms in allergy: An algorithm for alpha-Gal syndrome diagnosis and treatment, 2024 update

Darsow, U., Gelincik, A., Jappe, U., et al.Allergy. First published: 22 August 2024

An algorithm for the diagnosis and treatment of eosinophilic esophagitis in adults, 2024 update

Pfefferlé, M. and Greuter, T.Allergy. First published: 21 August 2024

Paediatric hospitalizations due to allergic reactions increasing in Finland and decreasing in Sweden

Saarimäki, L., Ekström, S., Protudjer, J.L.P., et al. Allergy. First published: 21 August 2024

NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis

Khalmuratova R, Ryu J-S, Hwang JH, et al.Allergy. First published: 21 August 2024

Infantile colic is associated with development of later constipation and atopic disorders

Stokholm J, Thorsen J, Schoos A-M, et al. Allergy. First published: 19 August 2024

Biomarkers for a less invasive strategy to predict children with eosinophilic esophagitis

Thulin H, Mansouri L, Altman M, et al. Allergy. First published: 19 August 2024

Nutritional and environmental exposures in athletes: Implications on the epithelial barrier function

Angelina, A., Pérez-Diego, M. and Palomares, O. Allergy. First published: 19 August 2024

Type 2 memory B cells: The repository of allergic memory?

Mulder, J., Dvorscek, A.R. and Ding, Z.Allergy. First published: 16 August 2024

Indirect case-matched comparison of anti-IL4Rα versus anti-IL5Rα on airway hyperresponsiveness

Chan, R., Stewart, K., Kuo, C.R. and Lipworth, B.Allergy. First published: 16 August 2024

Species-level, metagenomic and proteomic analysis of microbe-immune interactions in severe asthma

Jabeen MF, Sanderson ND, Tinè M, et al.Allergy. First published: 11 August 2024

Assessment of sIgE to rLep d 2 for detecting Lepidoglyphus destructor sensitization

Martin-Garcia, C., Murillo-Casas, A.D., Lázaro-Sastre, M.,et al.Allergy. First published: 11 August 2024

Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma

Fricker M, Harrington J, Hiles SA, Gibson PG. Allergy. First published: 08 August 2024

Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds

Kim M, Del Duca E, Dahabreh D, et al. Allergy. First published: 08 August 2024

Impact of a drug allergy education course for non-specialists: Findings from ADAPT—A randomized crossover trial

Lucas M, Mak HWF, Lee JTY, Kulkarni R, Chan SSC, Li PH. Allergy. First published: 07 August 2024

Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration

Traidl-Hoffmann C, Afghani J, Akdis C, et al.Allergy. First published: 04 August 2024

IgE glycosylation and impact on structure and function: A systematic review

McCraw AJ, Palhares LCGF, Hendel JL, et al.Allergy. First published: 04 August 2024

Key factors that influence quality of life in patients with IgE-mediated food allergy vary by age

Kubala SA, Young FD, Callier V, et al.Allergy. First published: 02 August 2024

Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response

Molina-Jiménez F, Ugalde-Triviño L, Arias-González L, et al.Allergy. First published: 02 August 2024

Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma

Rupani H, Busse WW, Howarth PH, et al.Allergy. First published: 01 August 2024

Trajectories of egg sensitization in childhood: Two birth cohorts in Asia and Europe

Nakamura T, Nakano T, Simpson A, et al.Allergy. First published: 01 August 2024

Vitamin D-FUT2 interaction and risk of lower respiratory tract infections in childhood

Brustad, N., Stokholm, J., Bønnelykke, K. and Chawes, B.L. Allergy. First published: 29 July 2024

An algorithm for the diagnosis and treatment of chronic inducible urticaria, 2024 update

Maurer, M., Bonnekoh, H., Grekowitz, E., et al. Allergy. First published: 26 July 2024

Anaplastic lymphoma kinase as a new therapeutic target in inflammatory itch

Voisin, T., Labit, E., Gaudenzio, N. and Basso, L. Allergy. First published: 26 July 2024

Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination

Buhre JS, Pongracz T, Geisen UM, et al. Allergy. First published: 25 July 2024

Disease modification in chronic spontaneous urticaria

Maurer M, Kolkhir P, Pereira MP, et al. Allergy. First published: 24 July 2024

From allergy to oncology: Targeting IL-4 to boost cancer immunotherapy

Consonni, F., Corsello, A. and Pegoraro, F. Allergy. First published: 24 July 2024

Mast cell responses in a mouse model of food allergy are regulated via a ST2/IL-4 axis

Ranjitkar, S., Krajewski, D., Tedeschi, C., et al. Allergy. First published: 24 July 2024

Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper

Pascal M, Bax HJ, Bergmann C, et al. Allergy. First published: 22 July 2024

Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults

Shah MM, Layhadi JA, Hourcade DE, et al. Allergy. First published: 20 July 2024

Effects of dupilumab on quality of life burden in refractory type 2 high unified airway disease

Stewart, K.E., Kuo, C.R., Chan, R. and Lipworth, B.J. Allergy. First published: 20 July 2024

Mesenchymal stromal cells effectively limit house dust mite extract-induced mixed granulocytic lung inflammation

Tynecka, M., Janucik, A., Tarasik, A., et al. Allergy. First published: 19 July 2024

Allergenic potency of various foods of mammalian origin in patients with α-Gal syndrome

Perusko M, Grundström J, Eldh M, et al. Allergy. First published: 15 July 2024

Pyroptosis, gasdermins and allergic diseases

Panganiban RA, Nadeau KC, Lu Q.Allergy. First published: 14 July 2024

Forecasting daily total pollen concentrations on a global scale

Makra L, Coviello L, Gobbi A, et al.Allergy. First published: 12 July 2024

Alpine altitude climate treatment improves asthma control, irrespective of biologics use

Fieten, K.B., Drijver-Messelink, M.T., Wolters, R., et al.Allergy. First published: 12 July 2024

Reaction severity and peach threshold amount during oral challenge in nonspecific lipid transfer protein allergy

Pérez-Sánchez, N., Rondón, C., Cañas, J.A., et al.Allergy. First published: 09 July 2024

Anti-rubella IgG serum levels predict risk for SARS-CoV-2 breakthrough infections

Hollstein, M.M., Dierks, S., Schön, M.P., et al.Allergy. First published: 09 July 2024

Person-centred care in allergen immunotherapy in a digital era

Ng, C.L. and Wang, D.Y. Allergy. First published: 09 July 2024

A recent patent in allergy & immunology: Biomarkers on allergen-specific memory B cells to predict allergen immunotherapy outcome

van Zelm, M.C., O'Hehir, R.E. and McKenzie, C.I. Allergy. First published: 09 July 2024

An algorithm for the diagnosis and treatment of Hymenoptera venom allergy, 2024 update

Sturm, G.J. and Arzt-Gradwohl, L. Allergy. First published: 08 July 2024

Human nasal epithelial cells express IL-5Rα but not the co-receptor CSF2RB and do not signal to IL-5

Sohail, A., Cho, L., Hacker, J., et al.Allergy. First published: 07 July 2024

Anaphylaxis and desensitization differently activate and induce IL-8 release by mast cells in a human peanut allergy in vitro model

Tontini, C., Bahri, R., Simpson, A. and Bulfone-Paus, S. Allergy. First published: 07 July 2024

Prevention of allergic airway and gut inflammation in humanized mice by lactobacilli, bifidobacteria, and butyrate

Khatri, R., Weigmann, B., Shahneh, F., et al.Allergy. First published: 07 July 2024

Genomic variants association with selective hypersensitivity reactions to amoxicillin and clavulanic acid

Nuñez, R., Fernandez-Santamaria, R., Salas, M., et al.Allergy. First published: 05 July 2024

Distinct roles of types 1 and 2 interferons in human eosinophil regulation: A multi-omics analysis

Sasaki, H., Miyata, J., Kawashima, Y., et al. Allergy. First published: 03 July 2024

MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment

Bartko, E.A., Mellergaard, M., Groen, S.S., et al.Allergy. First published: 02 July 2024

Legends of allergy and immunology: Otto Scheiner

Breiteneder, H. and Wiedermann, U. Allergy. First published: 02 July 2024

Citations: 342

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766

Citations: 147

EAACI guidelines: Anaphylaxis (2021 update)

Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377

Citations: 118

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990

Citations: 118

The role of peripheral blood eosinophil counts in COVID-19 patients

Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482

Citations: 114

Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease

Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449

Citations: 105

Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice

Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432

Citations: 90

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639

Citations: 88/h5>

The role of allergen-specific IgE, IgG and IgA in allergic disease

Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641

Citations: 82

COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676

Citations: 81

Advances and highlights in allergic rhinitis

Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389

Citations: 79

Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?

Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618

Citations: 76

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353

Citations: 74

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Citations: 73

Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches

Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826

Citations: 70

Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660

Citations: 69

Advances and highlights in biomarkers of allergic diseases

Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686

Citations: 69

Regulatory B cells, A to Z

Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.

Citations: 62

Advances and highlights in asthma in 2021

Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407

Citations: 62

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Citations: 61

The ingenious mast cell: Contemporary insights into mast cell behavior and function

Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99

The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414

Risk factors for severe and critically ill COVID-19 patients: A review

Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741

Advances and recent developments in asthma in 2020

Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update

Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541

Management of anaphylaxis due to COVID-19 vaccines in the elderly

Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review

Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016

Eczema herpeticum in atopic dermatitis

Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027

Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study

Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052

Direct assessment of individual skin barrier components by electrical impedance spectroscopy

Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132

Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis

Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154

Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy

Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193

Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma

Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202

Identification of Ulocladium chartarum as an important indoor allergen source

Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206

Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis

Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214

Legends of allergy and immunology: Sergio Bonini

Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229

Medical algorithm: Peri-operative management of mastocytosis patients

Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235

Open Access Agreements with Wiley



Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley

Free access

Junior Members Corner



Dear Junior Members,

The EAACI Summer symposium on Epithelial Cell Biology was held at the Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland, from July 25-26, 2024. During 2 exciting days, we attended different sessions by renowned speakers from different parts of the world with impressive talks on the epithelial barrier of the skin, gut and airway, metabolism, microbiome and their associated diseases.

Moreover, vibrant discussions were held during the 4 poster sessions, where most of the juniors presented more than 20 different posters that allowed us to learn and enrich ourselves while having informal discussions with the faculties and young colleagues. Of great importance was the networking activity during the lunch break on the first day, where we enjoyed a wonderful “lake walk with the experts” in which junior and seniors spent a pleasant time getting to know each other while enjoying a wonderful sunny midday.

We would like to take the opportunity to introduce the new EAACI Junior Member Assembly (JMA) for the next term 2024-2026, which has been elected after the annual congress. We welcome new members: Jitesh Chauhan (Basic and Clinical Immunology Section), Ozge Can Bostan (Asthma Section), Polina Pyatilova (Dermatology section), Fabio Ryser (ENT section), Bianca Olivieri (Food Allergy IG), Martha Jimenez Freites (Allergy immunotherapy IG), Gonçalo Silva (Environmental and occupational allergy IG), and Pedro Alves (Allied health and primary care IG), who joined previous board members: Ekaterina Khaleva (Paediatrics section), Riccardo Castagnoli (Allergy Diagnosis and systems medicine IG), Marina Labella (Drug Allergy IG), and Aspasia Karavelia, Ruben Fernandez-Santamaria and Leticia de las Vecillas, the new chair, the secretary and the past chair. We are very excited and looking forward to continue or even improve the current and future projects totally oriented to EAACI junior members.

Best regards,
The Junior Member Assembly


EAACI Patients Organisation Committee Corner



The POC Reunion in the Annual Congress 2023



The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.

Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.

Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.

The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.

Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.

Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.

The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.